Integrating [18F]-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors

Cancers, Год журнала: 2023, Номер 15(21), С. 5179 - 5179

Опубликована: Окт. 27, 2023

[18F]-FDG positron emission tomography with computed (PET/CT) imaging is widely used to enhance the quality of care in patients diagnosed cancer. Furthermore, it holds potential offer insight into synergic effect combining radiation therapy (RT) immuno-oncological (IO) agents. This achieved by evaluating treatment responses both at RT and distant tumor sites, thereby encompassing phenomenon known as abscopal effect. In this context, PET/CT can play an important role establishing timelines for RT/IO administration monitoring responses, including novel patterns such hyperprogression, oligoprogression, pseudoprogression, well immune-related adverse events. commentary, we explore incremental value combination IO precision solid tumors, offering supplementary insights recently released joint guidelines.

Язык: Английский

---

Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC

Advances in Bioscience and Biotechnology, Год журнала: 2023, Номер 14(04), С. 151 - 161

Опубликована: Янв. 1, 2023

Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1), have changed the treatment history of lung cancer, especially in field non-small cancer (NSCLC). 18F-FDG PET/CT, as a noninvasive effective examination technique, reflects location functional information tumor lesions through metabolic level glucose. Studies shown that PD-L1 may affect sugar metabolism cells. Therefore, PET/CT can be used to predict expression evaluate efficacy immunotherapy. This article mainly introduces relationship between NSCLC, advantages imaging mechanism based on research progress role response evaluation immunotherapy aiming provide reference for clinic.

Язык: Английский

---

Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?

Frontiers in Oncology, Год журнала: 2023, Номер 13

Опубликована: Окт. 4, 2023

In lung clinical trials with imaging, blinded independent central review double reads is recommended to reduce evaluation bias and the Response Evaluation Criteria Solid Tumor (RECIST) still widely used. We retrospectively analyzed inter-reader discrepancies rate over time, risk factors for related baseline evaluations, potential of machine learning predict discrepancies.We five BICR patients on immunotherapy or targeted therapy cancer. Double 1724 involving 17 radiologists were performed using RECIST 1.1. evaluated time according four endpoints: progressive disease declared (PDD), date (DOPD), best overall response (BOR), first (DOFR). Risk associated analyzed, two predictive models evaluated.At end trials, discrepancy rates between not different. On average, 21.0%, 41.0%, 28.8%, 48.8% PDD, DOPD, BOR, DOFR, respectively. Over was higher DOFR than increased as trial progressed, even after accrual completed. It rare readers find any disease, less 7% patients, at least one reader selected non-measurable only (NTL). Often some their target lesions (TLs) NTLs in different organs, ranges 36.0-57.9% 60.5-73.5% Rarely (4-8.1%) all TLs locations. Significant depending endpoint being considered. Prediction had a poor performance but positive value 80%. The classification obtained BOR.Predicting discordance necessitates having knowledge patient accrual, survival, probability discordances time. cancer although are known, they weakly significant, ability from data limited. To boost prediction accuracy, it would be necessary enhance baseline-derived features create new ones, considering other looking into optimal associations.

Язык: Английский

---

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer

Frontiers in Oncology, Год журнала: 2023, Номер 13

Опубликована: Ноя. 9, 2023

This study aimed to elucidate the relationship between dynamic genomic mutation alteration and pseudoprogression (PsPD)/hyperprogressive disease (HPD) in immunotherapy-treated advanced non-small-cell lung cancer (NSCLC), provide clinical evidence for identifying distinguishing PsPD HPD.Patients with NSCLC who were treated anti-PD1 enrolled. Whole blood was collected at baseline post image progression. Serum separated sequenced using 425-panel next-generation sequencing analysis (NGS).NGS revealed that not only single gene mutations associated PsPD/HPD before treatment, monitoring of whole-blood genome spectrum also varied greatly. Mutational burden, allele frequency%, relative circulating tumor DNA abundance indicated fold change after progression much higher HPD group.The profiles differed but true patients HPD. suggests whole-genome profile as NGS can distinguish from more effectively than detection, providing a novel method guiding immune treatment.

Язык: Английский

---

Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Дек. 4, 2023

Uveal melanoma (UV) is a rare and aggressive with poor 1-year survival. up to 50% of UV patients develop metastases, mainly the liver. Here, authors present 2-deoxy-2-[

Язык: Английский

---